testicular cancer, esophageal cancer, throat cancer, bladder cancer, stomach cancer, what is cancer, cancer horoscope, horoscope cancer,
breast cancer facts, testicular cancer symptoms, cervical cancer, cancer definition, cancer horoscope today, cancer love horoscope, ovarian cancer symptoms, symptoms of cancer, breast cancer symptoms, brain cancer symptoms, A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.
 |
| UT Southwestern’s Dr. Lu Le, left, and graduate student Amish Patel published a study that found by inhibiting a key protein, a rare, incurable type of soft-tissue cancer could be eradicated. |
In the study, published online today in Cell Reports, scientists found that inhibiting the action of a protein called BRD4 caused cancer cells to die in a mouse model of malignant peripheral nerve sheath tumors (MPNSTs).
“This study identifies a potential new therapeutic target to combat MPNST, an incurable type of cancer that is typically fatal,” said Dr. Lu Le, Assistant Professor of Dermatology at UT Southwestern and senior author of the study. “The findings also provide important insight into what causes these tumors to develop.”
MPNSTs are highly aggressive sarcomas that form around nerves. These tumors can develop sporadically, but about half of cases are in patients with a genetic disorder called neurofibromatosis type 1 (NF1) that affects 1 in 3,500 people. About 10 percent of NF1 patients will develop MPNST, which usually evolves from a benign but often large and disfiguring tumor called a plexiform neurofibroma.
Up to now, the preferred treatment for MPNST has been surgical removal, but that oftentimes is difficult or impossible due to the tumor’s location around nerves. Radiation and chemotherapy are other options, but their effectiveness is limited. The five-year survival rate for MPNST patients is about 50 percent.
By studying changes in cells as they evolved into cancerous MPNSTs, researchers in Dr. Le’s laboratory were able to determine that BRD4, a bromodomain protein that binds to DNA to regulate gene activation, is expressed at an unusually high level in MPNST cancer cells. This action caused another protein called BCL-2 to keep cancer cells from dying. Alternately, when researchers inhibited BRD4 either genetically in the mice or pharmacologically by administering a compound called JQ1, the tumors shrank.
“These treatments suppressed tumor growth and caused the cancer cells to undergo apoptosis, or cell death. This is why BRD4 inhibition is exquisitely effective against MPNSTs and may represent a paradigm shift in therapy for these patients,” Dr. Le said.
The same class of drug used in the experiments is currently being evaluated in phase 1 and 2 trials for treatment of leukemia and a subtype of lung cancer. Meanwhile, UT Southwestern is working with a pharmaceutical company to develop a similar BRD4-inhibiting drug to launch a clinical trial for MPNST patients.
New drugs are desperately needed to treat MPNST and provide hope to NF1 patients at highest risk for this cancer, said Dr. Le, who also serves as Co-director of UT Southwestern’s Comprehensive Neurofibromatosis Clinic. The clinic offers neurofibromatosis patients access to the latest clinical trials and treatments. Co-directed by Dr. Laura Klesse, Assistant Professor of Pediatrics, the clinic is part of the Harold C. Simmons Comprehensive Cancer Center and serves patients with all three types of hereditary neurofibromatosis, including the dominant NF1 type and rarer NF2 and Schwannomatosis forms.
Other UT Southwestern researchers involved in the study, all in Dermatology, were first author and graduate student Amish Patel; postdoctoral researchers Drs. Chung-Ping Liao and Zhiguo Chen; and research assistants Chiachi Liu and Yong Wang. The study was funded byUT Southwestern’s Disease-Oriented Clinical Scholars Program, the Dermatology Foundation, the Children’s Tumor Foundation, the National Cancer Institute, and the U.S. Department of Defense.
About UT Southwestern Medical Center
UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty includes many distinguished members, including five who have been awarded Nobel Prizes since 1985. Numbering more than 2,700, the faculty is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 91,000 hospitalized patients and oversee more than 2 million outpatient visits a year.
daily horoscope cancer, daily cancer horoscopepancreatic cancer symptoms, throat cancer symptoms, thyroid cancer symptoms, eye cancer symptoms, squamous cell carcinoma, carcinoma, symptoms of pancreatic cancer, cancer sign, signs of ovarian cancer, signs of lung cancer, oncologist, melanoma, adrenocortical carcinoma, leukemia, cancer, chemotherapy, breast, american cancer society,
No comments: